Principally grades 1-3 immune-mediated reactions for Keytrudaīest overall response (BOR) by RECIST 1.1 (19 patients)ĥ% complete response (CR), 26% objective response rate (ORR), 53% disease control rate (DCR) Principally grades 1-2 injection-site reactions for PV-10
Highlights of the SMR 2021 presentation :Ħ8% male median age of 72 years (range 28-90) 50% Stage IV M1b-dĬB-refractory status: 9% CTLA-4, 32% PD-1, 59% CTLA-4+PD-1 28, 2021 (GLOBE NEWSWIRE) - Provectus (OTCQB: PVCT) today announced that updated response, safety, and immune correlative data from the Company’s ongoing Phase 1b clinical trial of cancer immunotherapy PV-10 (rose bengal disodium), in combination with Keytruda (pembrolizumab), for the treatment of advanced cutaneous melanoma in patients refractory to immune checkpoint blockade (CB) ( NCT02557321: first expansion cohort) will be presented at the SMR 2021 Virtual Congress (the Society for Melanoma Research annual meeting), which is being held online from October 28 th to 31 st.Ī copy of the poster presentation is available on Provectus’ website at. 34.1 months median overall survival, 4.9 months median progression-free survivalīest overall response ( RECIST 1.1 ) : 5% CR, 26% ORR, 53% DCR (19 patients)
